10/09/2026
Considering regenerative medicine? Educate yourself before choosing where to go.
Two clinics can both tell you they offer “100 million stem cells.”
That does not mean they are offering the same biological product.
Where did the cells come from?
Who was the donor?
How were they processed and expanded?
How many passages did they undergo?
How were they characterized?
Were they tested for identity, purity, viability, potency and sterility?
How were they stored and transported?
What are the release criteria?
And perhaps most importantly: who independently verifies any of it?
These aren’t minor details. They are the product.
Research cited in our newest Project Redwood white paper shows significant donor-to-donor variability in MSCs. Mayo Clinic’s work highlights the importance of standardized manufacturing. FDA’s evolving cellular-therapy guidance is placing increasing attention on manufacturing and quality controls. And AABB standards provide independent frameworks spanning donor eligibility, processing, storage and administration.
Yet regenerative medicine is still too often marketed with one number:
“How many stem cells do I get?”
That’s the wrong question.
A dose is more than a number. Cell count tells you quantity. It does not, by itself, tell you quality, identity, purity, potency, sterility, consistency—or what happened to those cells before they reached you.
At Auragens, we believe patients deserve more than claims. They deserve verification.
Our latest Project Redwood white paper, THE PROCESS IS PART OF THE PRODUCT, examines what patients, physicians and the regenerative medicine industry should be asking as cellular medicine enters its next era.
If you’re considering stem cell therapy anywhere in the world, read this first. Then ask better questions.
“The Process Is Part of the Product”
Project Redwood | Auragens
Available now at Auragens.com
Or DM to be sent a copy directly